Summary of Key Points Core Viewpoint - On October 31, the Beijing Stock Exchange (BSE) saw a total trading volume of 1.299 billion shares and a trading value of 32.323 billion yuan, representing a decrease of 10.622 billion yuan compared to the previous trading day. A total of 219 stocks closed higher, indicating a positive market sentiment despite the drop in trading volume [1]. Trading Performance - The trading volume for the BSE was 1.299 billion shares, with a trading value of 32.323 billion yuan, down from the previous day by 10.622 billion yuan [1]. - Among the traded stocks, 219 stocks rose, accounting for 78.49% of the total, with notable gainers including Lijia Technology (up 13.91%), Deyuan Pharmaceutical (up 13.09%), and Sanyuan Gene (up 13.07%) [1]. - Conversely, 55 stocks declined, with Huifeng Diamond, Jiuling Technology, and Mezhigao experiencing the largest drops of 6.34%, 4.96%, and 4.57% respectively [1]. Active Stocks - A total of 93 stocks had a trading value exceeding 100 million yuan, with the highest trading values recorded for Beiterui (1.359 billion yuan), Fujida (999.5 million yuan), and Guozi Software (709.8 million yuan) [1]. - The trading activity was characterized by 46 stocks having a turnover rate exceeding 10%, with 8 stocks exceeding 20%. The highest turnover rates were seen in Digital Human (32.55%), Jinhua New Materials (28.91%), and Taikai Ying (27.85%) [1]. Notable Stock Details - Key stocks and their performance included: - Beiterui: Closing price 36.45 yuan, up 4.71%, turnover rate 3.29%, trading value 1.359 billion yuan [1]. - Guozi Software: Closing price 44.70 yuan, up 11.75%, turnover rate 26.35%, trading value 709.8 million yuan [1]. - Deyuan Pharmaceutical: Closing price 41.30 yuan, up 13.09%, turnover rate 12.64%, trading value 523.0 million yuan [1].

Core Insights - San Yuan Gene reported a revenue of 163 million yuan for the first three quarters of 2025, with a net cash flow from operating activities of 22.52 million yuan, indicating a strong performance in the biopharmaceutical sector [1][2] - The company is actively promoting innovation in research and development and intelligent manufacturing, aligning with national policies aimed at advancing the biopharmaceutical industry [1][2] Industry Developments - The biopharmaceutical industry is undergoing significant transformation, supported by national policies that encourage digital transformation and integration with new information technologies [1] - The Ministry of Industry and Information Technology and other departments have set a goal for comprehensive digital transformation of pharmaceutical enterprises by 2030, providing a clear direction for industry development [1] Company Initiatives - San Yuan Gene is focusing on building a dynamic digital twin platform for biopharmaceuticals, which integrates multi-source data and algorithmic models to enhance manufacturing flexibility and operational efficiency [1][2] - The company has established a smart ecosystem that covers the entire supply chain, enhancing product quality, production efficiency, and market competitiveness in the context of centralized procurement policies [2] Achievements and Future Plans - The company has made significant progress in its smart factory construction project, achieving key objectives in data integration and innovation-driven manufacturing [2] - San Yuan Gene has received accolades such as "2025 Advanced Intelligent Factory in Beijing" and "2025 Green Lighthouse Factory in Shanghai," reflecting its commitment to intelligent manufacturing [2] - Future plans include further integrating digital twin technology with AI models to create an open collaborative platform for the biopharmaceutical industry, providing innovative solutions for digital transformation [2]

| 专门委员会名称 | 委员 | 主任委员（召集人） | | --- | --- | --- | | 审计委员会 | 钱爱民、邵荣光、杨大军 | 钱爱民 | | 薪酬与考核委员会 | 邵荣光、钱爱民、杨大军 | 邵荣光 | | 战略与可持续发展 | 程永庆、范保群、胡左浩 | 程永庆 | | 委员会 | | | 二、调整后： 证券代码：920344 证券简称：三元基因 公告编号：2025-111 | 专门委员会名称 | 委员 | 主任委员（召集人） | | --- | --- | --- | | 审计委员会 | 钱爱民、邵荣光、许大海 | 钱爱民 | | 薪酬与考核委员会 | 邵荣光、胡左浩、杨大军 | 邵荣光 | | 战略与可持续发展 | 程永庆、范保群、胡左浩 | 程永庆 | | 委员会 | | | 北京三元基因药业股份有限公司 调整后的董事会专门委员会委员的任期自本次董事会审议通过 之日起至第四届董事会届满之日止，与公司第四届董事会任期一致。 关于调整公司第四届董事会专门委员会委员的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-110 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 27 日 北京三元基因药业股份有限公司 第四届董事会第九次会议决议公告 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 4.发出董事会会议通知的时间和方式：2025 年 10 月 16 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：董事会秘书以及公司其他高级管理人员列席了 会议。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 7.召开情况合法合规的说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程十庆、胡左浩因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《2025 年第三季度报告》 1.议案内容： 具体内容详见公司于 2025 年 10 月 29 日在北京证券交易所官网 （www.bse. ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

北京浩天律师事务所 HYLANDS LAW FIRM 中国北京市朝阳区东三环中路5号财富金融中心 3 层、11层、12层 12F Fortune Financial Center, No.5 Mid Rd, East 3rd Ring, Chaoyang District, Beijing 100020, China 电话 Tel: （86-10）65028888，传真 Fax: (86-10) 65028877 网址: http://www.hylandslaw.com 关于北京三元基因药业股份有限公司 2025年第三次临时股东会之法律意见书 致:北京三元基因药业股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《北京证券交 易所股票上市规则》等现行有效的法律法规、规范性文件,以及北京三元基因 药业股份有限公司章程》（以下简称"公司章程"）的规定,北京浩天律师事 务所（以下简称"本所"）接受北京三元基因药业股份有限公司（以下简称"公 司"）委托,指派本所康乃馨律师、戚萌律师(以下简称"本所律师")出席公 司 2025年第三次临时股东会会议(以下简称"本次股东会"),对本次股东会的 相关事项依 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-107 北京三元基因药业股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 17 日 2.会议召开地点：公司会议室 6.召开情况合法合规的说明： 3.会议召开方式：现场投票和网络投票相结合的方式 4.会议召集人：董事会 5.会议主持人：董事长程永庆 会议的召集、召开、议案审议程序符合《公司法》等有关法律、 法规和《公司章程》的规定。 出席和授权出席本次股东会的股东共 11 人，持有表决权的股份 总数 61,240,271 股，占公司有表决权股份总数的 50.2752%。 其中通过网络投票参与本次股东会的股东共 3 人，持有表决权的 股份总数 2,342,366 股，占公司有表决权股份总数的 1.9230%。 通过现场和网络参加本次股东会的中小股东（除公司董事、高级 管理人员及其关联方，以及单独或者合计持有公司 ...

Core Viewpoint - The A-share market shows a positive trend with the Shanghai Composite Index closing at 3897.56 points, above the six-month moving average, reflecting a slight increase of 0.21% [1] Group 1: Market Performance - The total trading volume of A-shares reached 1681.524 billion yuan today [1] - A total of 127 A-shares have surpassed the six-month moving average, indicating a bullish sentiment in the market [1] Group 2: Individual Stock Performance - Stocks with significant deviations from the six-month moving average include: - Ainanju (证券代: 920770) with a deviation rate of 9.77% and a daily increase of 12.36% [1] - Huifeng Diamond (证券代: 920725) with a deviation rate of 5.80% and a daily increase of 12.63% [1] - Kaitian Gas (证券代: 920010) with a deviation rate of 5.69% and a daily increase of 7.07% [1] - Other notable stocks with smaller deviations include Jiangzhong Pharmaceutical, Qingdao Port, and Ningbo Energy, which have just crossed the six-month moving average [1]